GSK Settles Anemia Drug Patent Claims On Eve Of Trial
British pharmaceutical giant GlaxoSmithKline settled claims it infringed two patents for anemia treatments with patent holder FibroGen Inc. and licensee Astellas Pharma just as the case went to trial Monday in...To view the full article, register now.
Already a subscriber? Click here to view full article